Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline

Purpose In April 2017, the American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Clinically Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. Results The ASCO Expert Panel determined that the recommendations from the Clinically Localized Prostate Cancer guideline were clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Clinically Localized Prostate Cancer guideline except for two recommendations on cryosurgery. The two recommendations covering cryosurgery were not endorsed because the panel found that there is insufficient evidence to support the use of cryotherapy in this setting. Recommendations The ASCO Expert Panel endorsed all but two of the original guideline recommendations as written and offered a series of discussion points to guide practice.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Sep 05 [Epub ahead of print]

Justin E Bekelman, R Bryan Rumble, Ronald C Chen, Thomas M Pisansky, Antonio Finelli, Andrew Feifer, Paul L Nguyen, D Andrew Loblaw, Scott T Tagawa, Silke Gillessen, Todd M Morgan, Glenn Liu, Neha Vapiwala, John J Haluschak, Andrew Stephenson, Karim Touijer, Terry Kungel, Stephen J Freedland

Justin E. Bekelman and Neha Vapiwala, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ronald C. Chen, University of North Carolina at Chapel Hill, Chapel Hill; Stephen J. Freedland, Durham VA Medical Center, Durham, NC; Thomas M. Pisansky, Mayo Clinic, Rochester, MN; Antonio Finelli, Princess Margaret Cancer Centre, University Health Network; Andrew Feifer, Trillium Health Partners, University of Toronto; D. Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Paul L. Nguyen, Dana-Farber Cancer Institute, Boston, MA; Scott T. Tagawa, Weill Cornell Medicine, New York, NY; Silke Gillessen, Kantonsspital St Gallen, St Gallen, Switzerland; Todd M. Morgan, University of Michigan, Ann Arbor, MI; Glenn Liu, University of Wisconsin Carbone Cancer Center, Madison, WI; John J. Haluschak, Kettering Medical Center-Pavillon, Kettering; Andrew Stephenson, Cleveland Clinic, Cleveland, OH; Karim Touijer, Memorial Sloan Kettering Cancer Center, New York, NY; Terry Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME; and Stephen J. Freedland, Cedars-Sinai Medical Center, Los Angeles, CA.